Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950123-11-016581
Filing Date
2011-02-22
Accepted
2011-02-22 17:05:05
Documents
1

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D/A c13038sc13dza.htm SC 13D/A 22824
  Complete submission text file 0000950123-11-016581.txt   24780
Mailing Address P.O. BOX 110526 RESEARCH TRIANGLE PARK NC 27709
Business Address 4101 RESEARCH COMMONS 79 T.W. ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 919-316-6300
Talecris Biotherapeutics Holdings Corp. (Subject) CIK: 0001405197 (see all company filings)

EIN.: 202533768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-85250 | Film No.: 11629244
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1585 BROADWAY SUITE 2376 NEW YORK NY 10036
Business Address 1585 BROADWAY SUITE 2376 NEW YORK NY 10036 212-969-3335
Grifols SA (Filed by) CIK: 0001438569 (see all company filings)

EIN.: 000000000
Type: SC 13D/A
SIC: 2834 Pharmaceutical Preparations